Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial

scientific article published on 29 January 2007

Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/IAI.01673-06
P932PMC publication ID1865725
P698PubMed publication ID17261612
P5875ResearchGate publication ID6541928

P50authorHelena KäyhtyQ111990066
Merja VäkeväinenQ124818481
Terhi KilpiQ124818485
Nina EkströmQ124818494
P2093author name stringJouko Verho
P2860cites workA comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlersQ73594815
Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodiesQ74037367
Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncTQ74541105
Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhoodQ77367132
Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjuQ79162711
Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infantsQ81012140
Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccineQ81104099
Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infantsQ24795590
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine TrialQ33557154
Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharidesQ33867137
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlersQ33874664
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center GroupQ33896897
Efficacy of a pneumococcal conjugate vaccine against acute otitis mediaQ33932973
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialQ33986009
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infantsQ34205630
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trialQ34220731
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumoniaQ34917765
Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4.Q35108576
Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cellsQ35229917
Functional capacities of clonal antibodies to Haemophilus influenzae type b polysaccharide.Q35428480
The Role of Antibody and Complement in the Reticuloendothelial Clearance of Pneumococci from the BloodstreamQ40161697
Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis mediaQ44373346
Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniaeQ44736820
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infectionQ46198228
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccineQ46849891
Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccineQ47218152
Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccinesQ48023963
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.Q52039837
Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.Q52041060
Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and ChildrenQ52051185
Pathogenesis of Pneumococcal InfectionQ59647738
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy studyQ61622800
Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidityQ64131545
Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study GroupQ68061882
Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type bQ68791967
Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody productionQ70018803
Immunogenicity of heptavalent pneumococcal conjugate vaccine in infantsQ71072124
Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infantsQ71569665
Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugatesQ72133190
Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniaeQ73264844
Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6BQ73281054
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infantsQ73298427
Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccineQ73402133
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectFinlandQ33
antibodyQ79460
P304page(s)1794-1800
P577publication date2007-01-29
P1433published inInfection and ImmunityQ6029193
P1476titleFunctional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial
P478volume75

Reverse relations

cites work (P2860)
Q35867546A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice
Q33825652Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo
Q83981333Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization
Q33601848Antibodies to the HMW1/HMW2 and Hia adhesins of nontypeable haemophilus influenzae mediate broad-based opsonophagocytic killing of homologous and heterologous strains
Q86049387Correlation of pneumococcal antibody concentration and avidity with patient clinical and immunologic characteristics
Q47659427Determination of avidity of IgG against protein antigens from Streptococcus pneumoniae: assay development and preliminary application in clinical settings
Q47841000IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants
Q34738780Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines
Q38875984Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults
Q38443063Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose
Q37130191Next generation protein based Streptococcus pneumoniae vaccines
Q34444503Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age
Q28394642Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine
Q35136893Pneumococcal conjugate vaccination at birth in a high-risk setting: no evidence for neonatal T-cell tolerance
Q37316015Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.
Q34998490Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness
Q35868890Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.
Q34170021Protein carriers of conjugate vaccines: characteristics, development, and clinical trials
Q49568885Re-emergence of pneumococcal colonization by vaccine serotype 19F in persons aged ≥5 years after 13-valent pneumococcal conjugate vaccine introduction-Alaska, 2008-2013.
Q33803550Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
Q40943510Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines
Q34309712Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae
Q46144154Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries
Q24644461Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B
Q37730648T cells control the generation of nanomolar-affinity anti-glycan antibodies
Q38160248The history of pneumococcal conjugate vaccine development: dose selection
Q28084920The host immune dynamics of pneumococcal colonization: implications for novel vaccine development
Q37197138Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes